These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24394931)

  • 21. Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.
    Morgan T; Palapattu G; Wei J
    Curr Urol Rep; 2015 Sep; 16(9):63. PubMed ID: 26169584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

  • 23. [Prostate cancer screening benefit very low, even after 13 years].
    Blanker MH; Noordzij MA
    Ned Tijdschr Geneeskd; 2014; 158():A8349. PubMed ID: 25492737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 25. [Related biomarkers in the diagnosis of prostate cancer].
    Xu YM; Liu HZ
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):937-40. PubMed ID: 26665686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
    Stampfer MJ; Jahn JL; Gann PH
    J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
    [No Abstract]   [Full Text] [Related]  

  • 27. [Reply].
    Lellig K; Buchner A; Stief C
    Urologe A; 2015 Jun; 54(6):870. PubMed ID: 26280043
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma.
    Thompson IM; Ankerst DP; Tangen CM
    J Natl Cancer Inst; 2010 Sep; 102(17):1299-301. PubMed ID: 20724727
    [No Abstract]   [Full Text] [Related]  

  • 29. The Roles of Providers and Patients in the Overuse of Prostate-Specific Antigen Screening in the United States.
    Guo F; He D
    Ann Intern Med; 2015 Oct; 163(8):650-1. PubMed ID: 26502132
    [No Abstract]   [Full Text] [Related]  

  • 30. Good ethics begins with sound medicine: prostate cancer screening and chemoprevention.
    Ennis R; Jotkowitz A
    Am J Bioeth; 2011 Dec; 11(12):26-7. PubMed ID: 22146026
    [No Abstract]   [Full Text] [Related]  

  • 31. PSA screening: the USPSTF got it right.
    Lefevre M
    J Fam Pract; 2013 Nov; 62(11):617, 619. PubMed ID: 24288702
    [No Abstract]   [Full Text] [Related]  

  • 32. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 34. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
    Loeb S; Metter EJ; Carter HB
    J Natl Cancer Inst; 2011 Nov; 103(21):1636-7; author reply 1637. PubMed ID: 21926375
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
    Vickers AJ
    J Natl Cancer Inst; 2011 Nov; 103(21):1635-6. PubMed ID: 21926376
    [No Abstract]   [Full Text] [Related]  

  • 37. Is Prostate-Specific Antigen Screening "Proven Ineffective Care"?
    Barry MJ; Albertsen PC
    Ann Intern Med; 2016 May; 164(10):687-8. PubMed ID: 26902323
    [No Abstract]   [Full Text] [Related]  

  • 38. [Regarding the duty of care of a general practitioner for a continuously increasing, elevated PSA level (OLG Koblenz, decision dated 18 June 2015 - 5 U 66/15)].
    Dahm FJ
    Urologe A; 2016 Jul; 55(7):949-51. PubMed ID: 27335093
    [No Abstract]   [Full Text] [Related]  

  • 39. States renewing attention to prostate cancer.
    Rossiter C
    NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022
    [No Abstract]   [Full Text] [Related]  

  • 40. A rational basis for chemoprevention of prostate cancer.
    Huang CJ; Baum ML
    Am J Bioeth; 2011 Dec; 11(12):27-9. PubMed ID: 22146027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.